172results about How to "Solve the lack of activity" patented technology

An electrode/electrolyte structure is prepared by a plurality of methods. An unsintered (possibly bisque fired) moderately catalytic electronically-conductive or homogeneous mixed ionic electronic conductive electrode material is deposited on a layer composed of a sintered or unsintered ionically-conductive electrolyte material prior to being sintered. A layer of particulate electrode material is deposited on an unsintered (“green”) layer of electrolyte material and the electrode and electrolyte layers are sintered simultaneously, sometimes referred to as “co-firing,” under conditions suitable to fully densify the electrolyte while the electrode retains porosity. Or, the layer of particulate electrode material is deposited on a previously sintered layer of electrolyte, and then sintered. Subsequently, a catalytic material is added to the electrode structure by infiltration of an electrolcatalyst precursor (e.g., a metal salt such as a transition metal nitrate). This may be followed by low temperature firing to convert the precursor to catalyst. The invention allows for an electrode with high electronic conductivity and sufficient catalytic activity to achieve high power density in an ionic (electrochemical) device such as fuel cells and electrolytic gas separation systems.

The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.

The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.

This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.

Devices, systems and methods are disclosed that allow a patient to self-treat neurodegenerative diseases, such as dementia, Alzheimer's disease, ischemic stroke, post-concussion syndrome, chronic traumatic encephalopathy and the like by electrical noninvasive stimulation of a vagus nerve. The system comprises a handheld stimulator that is applied to the surface of the patient's neck, wherein the stimulator comprises or is joined to a smartphone. A camera of the smartphone may be used to position and reposition the stimulator to a particular location on the patient's neck. The system may also comprise a base station that is used to meter the charging of a rechargeable battery within the stimulator. The base station and stimulator transmit data to one another regarding the status of a stimulation session.

The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB₁ and/or the CB₂ cannabinoid receptor. Preferably the cannabinoid is a cannabidiol (CBD) type compound or derivative thereof.

The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type n diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.

The present invention relates to a catalyst for preparing hydrocarbons of carbon dioxide and more particularly, the Fe—Cu—K/γ—Al₂O₃ catalyst prepared by impregnation which enables producing hydrocarbons in high yield for more than 2000 hours due to its excellent activity and stability.

This invention provides a novel polymerization catalyst other than antimony compounds, polyester produced by using the same and a process for producing polyester. The polycondensation catalyst of this invention is a polyester polymerization catalyst comprising an aluminum compound and a phosphorus compound having a specific structure. Further, this invention relates to polyester produced by using this polyester polymerization catalyst and a process for producing polyester. Further, this invention relates to fibers, films and hollow molded articles comprising the polyester.

An object of the present invention is to provide an antibacterial medical equipment which has sufficient antibacterial activity in vivo and is excellent in compatibility with living tissues, and also can maintain antibacterial activity over a long period and has high safety.

An antibacterial medical equipment characterized in that inositol phosphate is bonded to a Ca compound of a medical equipment whose surface is at least coated with a layer of the Ca compound, or a medical equipment comprising the Ca compound. The antibacterial medical equipment as described above, wherein silver ions are bonded to the inositol phosphate. A method for producing an antibacterial medical equipment, which comprises bringing a medical equipment whose surface is at least coated with a layer of a Ca compound, or a medical equipment comprising a Ca compound into contact with an aqueous solution of inositol phosphate to obtain an antibacterial medical equipment in which inositol phosphate is bonded to the Ca compound. The method for producing an antibacterial medical equipment, wherein inositol phosphate is bonded to the Ca compound and then the Ca compound is brought into contact with an aqueous solution containing silver ions to obtain an antibacterial medical equipment in which silver ions are bonded to the inositol phosphate.

The invention relates to decontaminating composites, and methods, compositions, and kits comprising the same. In some aspects, the invention relates to a decontaminating composite, comprising a perhydrolase associated with a carbon nanotube, that is useful for producing peracids.

According to the present invention, a process is provided for producing an acyl group-containing composition that includes a step of reacting a long chain N-acyl acidic amino acid anhydride with one or more compounds which have, per molecule, m functional groups of one kind or more selected from the group consisting of hydroxyl, amino and thiol groups in an aqueous solvent and/or a mixed solvent of water and an organic solvent (reaction step). The process makes it possible to produce an acyl group-containing composition that is free from coloration under moderate conditions.

Cellulose contained in plant fiber material is hydrolyzed with the use of a pseudo-molten cluster acid as a hydrolysis catalyst to produce saccharide, most of which is glucose. After the glucose is produced, the saccharide is precipitated with the use of an organic solvent, and the saccharide including a solidified saccharide during the hydrolysis and the precipitated saccharide is separated from residues and the cluster acid.

This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.

The present invention relates to a catalytic continuous process for producing methyl methacrylate, said process comprising the step of reacting methacrolein with oxygen and methanol in the presence of a heterogeneous noble-metal-containing catalyst in an oxidative esterification reaction to give methyl methacrylate, characterized in that the stationary concentration of the starting material methacrolein is equal to or less than 12% by weight based on the total weight of the reaction mixture in the reactor, and the ratio F between the total liquid volume within the reactor expressed in litres divided by the total weight of catalyst in the reactor expressed in kilograms is equal to or less than 4.

A photocatalytic coating composition comprising a photocatalyst, a silicon alkoxide, a zirconium compound, colloidal silica, and a liquid medium, wherein a content of the zirconium compound in terms of zirconium atoms is 0.3 to 3 times by mole a content of the silicon alkoxide in terms of silicon atoms, which can form a coating film of a photocatalyst with a high adhesion strength to a substrate.

This invention relates to certain non-silicone vulcanized rubber articles that are made from at least a majority by weight of vulcanized styrene butadiene rubber that include silver-based compounds to provide highly desirable long-term antimicrobial characteristics within the cured rubber articles. Such articles are in either solid or blown (foam or sponge) state (or combinations of both in multilayered forms) and can be utilized in a variety of different applications. This invention encompasses the presence of non-sulfur-based curing systems and agents, such as peroxide curing, that permit vulcanization and do not irreversibly bind silver ions thereto, thereby resulting in long-term antimicrobial performance of the ultimate rubber article itself. This invention also encompasses certain non-silicone pre-vulcanized raw rubber formulations made from at least a majority by weight of styrene butadiene rubber that include silver-based components to provide highly desirable long-term antimicrobial characteristics within the ultimate cured rubber articles made therefrom.

The present invention relates to a method for producing a Ti/V supported catalyst useful in polymerization of ethylene and copolymerization of ethylene and alpha-olefin. The method includes a treatment, by a titanium compound and a vanadium compound, of the magnesium-containing carrier, which is obtained by reaction of an organomagnesium compound of the structure of MgPh2.nMgCl2.mR2O (n=0.37~0.7; m>=1; R2O=ether; Ph=phenyl) with an organic chloride compound in a mole ratio of organic chloride compound/Mg>=0.5, at -20~80° C. According to the method for producing the catalyst, it is possible to provide a catalyst which can control the distribution of molecular weight, and when polymerization is performed using this catalyst, it is possible to restrain the inactivation and to secure a sufficient activity. Moreover, the polymer produced by the use of this catalyst proves to have a high bulk density and an adjusted particle size distribution.